Form 4: Integra LifeSciences Executive Harvinder Singh Reports Stock Transactions
SEC Form 4
EVP & President, International, Harvinder Singh, reports transactions involving Integra LifeSciences Holdings Corp. stock, including the vesting of restricted stock units and stock options.
Summary
- On March 11, 2025, Harvinder Singh, EVP & President, International at Integra LifeSciences Holdings Corp., reported several transactions.
- These transactions included the vesting of 2,356 restricted stock units, the disposition of 647 shares to cover tax obligations at a price of $23.95, and the acquisition of 9,508 shares.
- Following these transactions, Singh directly owns 13,252 shares of common stock.
- Singh also reported owning 34,531 restricted stock units and 20,133 non-qualified stock options.
- The restricted stock units vest in three tranches, 33% on the first and second anniversaries and 34% on the third anniversary of the grant date of March 11, 2024.
- The stock options vest 25% annually over four years from the grant date of March 11, 2025.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation. There are no indications of unusual activity or concerns.
Positives
- The vesting of restricted stock units and stock options indicates a form of compensation and alignment of the executive's interests with the company's performance.
Negatives
- The disposition of shares to cover tax obligations, while standard, slightly reduces the executive's direct holdings.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors to gauge executive sentiment and potential future stock performance.
Comparison to Industry Standards
- Executive compensation packages often include a mix of salary, stock options, and restricted stock units.
- The vesting schedules described are fairly standard, aligning with typical industry practices for incentivizing long-term performance.
- Comparing the size of the stock option grants and restricted stock unit awards to those of executives at similar-sized medical device companies (e.g., NuVasive, Globus Medical) could provide further context.
Stakeholder Impact
- The transactions have a minor impact on shareholders, reflecting standard executive compensation practices.
- Employees may view the vesting of executive stock options and restricted stock units as a positive sign of company performance.
Key Dates
| Date | Description |
|---|---|
| 03/11/2024 | Grant date of restricted stock units, vesting 33% on the first and second anniversaries and 34% on the third anniversary. |
| 03/11/2025 | Date of reported transactions: vesting of restricted stock units, disposition of shares for taxes, acquisition of shares, and grant date of stock options. |
| 03/13/2025 | Date of signature of the report. |
| 03/11/2033 | Expiration date of non-qualified stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.